Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7869814 | 0.90 | ZDHHC7 (0.41) | MGAMGAASIMGAM2SMN1; SMN2 | |
| SCHEMBL29110828 | 0.87 | GAA (0.34) | MGAMGAASIMGAM2SMN1; SMN2 | |
| SCHEMBL8986712 | 0.82 | MGAM (0.34) | MGAMGAASIMGAM2SMN1; SMN2 | |
| SCHEMBL5792988 | 0.81 | MGAM (0.42) | MGAMGAASIMGAM2SMN1; SMN2 | |
| SCHEMBL143815 | 0.80 | ALDH1A1 (0.50) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL22207048 | 0.80 | SOAT1 (0.46) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL926431 | 0.79 | — | — | |
| SCHEMBL14459543 | 0.79 | — | — | |
| SCHEMBL196133 | 0.79 | — | — | |
| SCHEMBL30600798 | 0.78 | SOAT1 (0.43) | MGAMGAASIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113967258-B | FAP-activated therapeutic agents and related uses | 塔夫茨大学信托人 | 2024-07-02 | — | — | CN | disclosed |
| US-12023316-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-07-02 | — | — | US | disclosed |
| US-11925655-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-03-12 | — | — | US | disclosed |
| EP-4299134-A2 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | Bach Biosciences, LLC (US) | 2024-01-03 | — | — | EP | disclosed |
| US-20230390409-A1 | FAP-ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES | AVACTA LIFE SCIENCES LIMITED (GB) | 2023-12-07 | — | — | US | disclosed |
| CN-117042808-A | FAP activated serum half-life extending therapeutic conjugates | 阿瓦克塔生命科学有限公司 | 2023-11-10 | — | — | CN | disclosed |
| EP-4237012-A1 | FAP-ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES | Avacta Life Sciences Limited (GB) | 2023-09-06 | — | — | EP | disclosed |
| EP-3154594-B1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES LLC (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20230080775-A1 | POLYISOCYANATE PREPARATIONS | COVESTRO DEUTSCHLAND AG (DE) | 2023-03-16 | — | — | US | disclosed |
| CN-107312009-B | Quinoline compound, preparation method, intermediate, pharmaceutical composition and application thereof | 上海医药集团股份有限公司 | 2022-09-20 | — | — | CN | disclosed |
| US-20020155565-A1 | FAP-activated anti-tumor compounds | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-10-24 | — | — | US | disclosed |
| WO-2002038591-A1 | FAP-ACTIVATED ANTI-TUMOR COMPOUNDS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-05-16 | — | — | WO | disclosed |
| WO-2002038590-A1 | FAP-ALPHA-ACTIVATED ANTI-TUMOR COMPOUNDS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-05-16 | — | — | WO | disclosed |
| WO-2002038187-A1 | FAP-ACTIVATED ANTI-TUMOUR PRODRUG | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-05-16 | — | — | WO | disclosed |
| EP-1180116-A2 | FAP-ACTIVATED ANTI-TUMOR COMPOUNDS | Boehringer Ingelheim Pharma KG (DE) | 2002-02-20 | — | — | EP | disclosed |
| WO-2000071571-A2 | FAP-ACTIVATED ANTI-TUMOR COMPOUNDS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-11-30 | — | — | WO | disclosed |
| US-3950362-A | OXABICYCLOOCTANES AND PROCESS FOR THEIR MANUFACTURE | CIBA-GEIGY CORPORATION (US) | 1976-04-13 | — | — | US | disclosed |
| US-3946032-A | Acetal derivatives of 6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine-1-carboxaldehyde | CIBA-GEIGY CORPORATION (US) | 1976-03-23 | — | — | US | disclosed |
| US-3941813-A | Dioxatricyclodecanes and process for their manufacture | CIBA-GEIGY CORPORATION (US) | 1976-03-02 | — | — | US | disclosed |
| US-3941799-A | 6-Substituted-11b-phenyl-3, 11bH-oxazirino[2,3-d]-s-triazol[4,3-a][1,4]benzodiazepines | CIBA-GEIGY CORPORATION (US) | 1976-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020155565-A1 | FAP-activated anti-tumor compounds | FAP, FIBP, DNPEP | MGAM 664/4885GAA 168/4885SI 38/4885 |
| US-20230390409-A1 | FAP-ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES | FAP, FIBP, FUCA2 | MGAM 339/4885GAA 37/4885SI 24/4885 |
| US-12023316-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | MGAM 1092/4885GAA 47/4885SI 339/4885 |
| US-11925655-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | MGAM 925/4885GAA 85/4885SI 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.